Contractor intelligence · computed from public award records
SAFE PHARMACEUTICALS
- Awards won
- 67
- Known value
- USD 6.9M
- First award
- 11 Nov 2018
- Most recent
- 22 Jul 2019
Wins by funder
| Funder | Awards | Known value | Most recent |
|---|---|---|---|
| World Bank | 67 | USD 6.9M | 22 Jul 2019 |
Where the work is
EG · 67
Sources
The most recent award records behind the figures above. Every number on this page is computed from records like these — nothing is estimated or editorial.
- alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 109K · World Bank
- all technical offers are acceptable The Sofosbuvir 400mg , Daclatasvir 60 mg and Ribavirin drugs · 22 Jul 2019 · USD 107K · World Bank
- alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 105K · World Bank
- all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 22 Jul 2019 · USD 107K · World Bank
- alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 106K · World Bank
- alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 106K · World Bank
- all technical offers are acceptable for the sofosbuvir 400 mg, daclatavir 60 mg drugs . · 22 Jun 2019 · USD 106K · World Bank
- All technical offers are acceptable for the sofosbuvir 400mg, Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 106K · World Bank
- All technical offers are acceptable for the sofosbuvir 400mg, Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 109K · World Bank
- Purchasing of Hep-C medications · 13 Jun 2019 · USD 105K · World Bank
- All technical offers are acceptable for the sofosbuvir 400mg, Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 105K · World Bank
- All technical offers are acceptable for the sofosbuvir 400mg, Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 106K · World Bank
- All technical offers are acceptable for the sofosbuvir 400mg, Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 105K · World Bank
- all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 106K · World Bank
- all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 106K · World Bank
- all technical offers are accepted for The Sofosbuvir 400mg , Daclatasvir 60 mg drugs · 12 Nov 2018 · USD 96K · World Bank
- all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg · 12 Nov 2018 · USD 96K · World Bank
- all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 12 Nov 2018 · USD 96K · World Bank
- all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 11 Nov 2018 · USD 95K · World Bank
- all technical offers are accepted for The Sofosbuvir 400mg , Daclatasvir 60 mg drugs · 11 Nov 2018 · USD 95K · World Bank
Method
Computed from 67 award records ingested from official disclosure sources (World Bank, Inter-American Development Bank, and published contract-award notices). Values are shown in USD where the source published one; entity identity is resolved conservatively and reviewed. GLODA is not affiliated with any funder or contractor shown. Last computed 15 Sept 2026.